Literature DB >> 6594763

Potential of liposomes to ameliorate anthracycline-induced cardiotoxicity.

A Rahman, A Fumagalli, A Goodman, P S Schein.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6594763

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  9 in total

1.  Phase I study of liposomal daunorubicin in patients with acute leukemia.

Authors:  J Cortes; S O'Brien; E Estey; F Giles; M Keating; H Kantarjian
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

2.  Early evaluation of liposomal daunorubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphoma.

Authors:  D S Richardson; S M Kelsey; S A Johnson; M Tighe; J D Cavenagh; A C Newland
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

3.  Antitumor and toxicity evaluation of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes.

Authors:  A Rahman; A Fumagalli; B Barbieri; P S Schein; A M Casazza
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Comparative immunotoxicity of free doxorubicin and doxorubicin encapsulated in cardiolipin liposomes.

Authors:  A Rahman; A Ganjei; J R Neefe
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome).

Authors:  P Guaglianone; K Chan; E DelaFlor-Weiss; R Hanisch; S Jeffers; D Sharma; F Muggia
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

Review 6.  Liposomal encapsulated anthracyclines: new therapeutic horizons.

Authors:  F M Muggia
Journal:  Curr Oncol Rep       Date:  2001-03       Impact factor: 5.945

7.  Immunotoxicity of multiple dosing regimens of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes.

Authors:  A Rahman; A Joher; J R Neefe
Journal:  Br J Cancer       Date:  1986-09       Impact factor: 7.640

Review 8.  Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.

Authors:  Atiar M Rahman; Syed Wamique Yusuf; Michael S Ewer
Journal:  Int J Nanomedicine       Date:  2007

9.  A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer.

Authors:  K J O'Byrne; A L Thomas; R A Sharma; M DeCatris; F Shields; S Beare; W P Steward
Journal:  Br J Cancer       Date:  2002-07-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.